T. Rowe Price Investment Management, Inc.
Position in DYN — Dyne Therapeutics, Inc.
CIK 1897612
BALTIMORE, MD
Position in DYN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$558,146,572
+$215,062,432 QoQ
Shares Held
30,785,801
+75.5% QoQ
Ownership
21.6%
of shares outstanding
% of Portfolio
0.39%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 98.8085773698076.ToString("F0")%
Shared 0.ToString("F0")%
None 1.1914226301924058.ToString("F0")%
Common Shares in DYN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026T. Rowe Price Investment Management, Inc. holds $9,767,505,959 across 47 Biotechnology names. DYN ranks #5 (5.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,193,324 | $1,718,315,111 | |
| 2 | CYTK |
Cytokinetics Inc
|
17,523,840 | $1,154,996,294 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
10,300,984 | $867,033,823 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
12,126,017 | $704,642,847 | |
| 5 | DYN |
Dyne Therapeutics, Inc.
This page
|
30,785,801 | $558,146,572 | |
| 6 | BNTX |
BioNTech SE
|
5,856,073 | $520,487,768 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
6,159,027 | $462,481,337 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
5,464,997 | $455,179,600 |
All Filings in DYN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $558,146,572 | 30,785,801 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $343,084,140 | 17,540,089 | Shares | Sole | 2026-02-19 | |
| 2025-09-30 | $35,577,138 | 2,812,422 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $17,074,976 | 1,793,590 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $12,217,018 | 1,167,975 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||